Proxim

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Proxim

Proxim is a medicine whose active ingredient is Cefixime, classified as a third-generation cephalosporin antibiotic. It functions as a powerful bactericidal agent used to eliminate bacterial pathogens and is available only by prescription.


Quick Facts

Property Description
Active ingredient Cefixime (INN)
Form Tablets, Capsules, Oral Suspension
Pharmacological Class Beta-Lactam Antibiotic (Third-Generation Cephalosporin)
General Purpose Anti-infective agent (eliminates bacterial pathogens)
Origin Synthetic

What Type of Antibiotic is Proxim?

Proxim is a member of the third-generation cephalosporin class, a type of beta-lactam antibiotic. This classification defines Cefixime as a synthetic compound with a broad spectrum of activity against many common susceptible microorganisms (bacteria). This class of antibiotics is widely employed in clinical practice due to its efficacy against various bacterial species. Cefixime is clinically recognized for its reliable efficacy against common respiratory and urinary tract pathogens, establishing it as a primary oral agent in its class. As a single-ingredient product, its therapeutic efficacy depends entirely on the Cefixime molecule, serving exclusively as an anti-infective agent.

Cefixime Composition and Form

The core component of the medicine is Cefixime, which is the sole active ingredient across all formulations. Proxim is designed for oral administration, meaning it is taken by mouth, and is commonly supplied as tablets, capsules, and an oral suspension. The liquid oral suspension form is crucial for flexible and accurate dosing, particularly for pediatric patients. Cefixime is efficiently absorbed following oral ingestion, confirming its reliability as a non-injectable treatment. All forms contain necessary pharmaceutical excipients—inactive ingredients—which are necessary to ensure proper systemic absorption and delivery of the active substance.

What Is Proxim’s General Therapeutic Purpose?

The general purpose of Proxim is to serve as an agent that controls and eliminates bacterial infections. It achieves this by causing the inhibition of bacterial cell wall synthesis, a vital structural process for the survival of the pathogen. By targeting and disrupting the bacteria's rigid outer barrier, Cefixime ensures the pathogen is killed rapidly and irreversibly. This foundational function of killing bacteria, known as bactericidal activity, is what makes the medicine effective.

Regulatory References

  1. third-generation cephalosporin antibiotic
  2. Efficacy against various bacterial species

What side effects are possible with Proxim?

The safety profile for Proxim (Cefixime) is defined by regulatory authorities based on documented adverse reactions categorized by frequency and affected body systems. This information is derived strictly from government-approved labeling.

Officially Documented Adverse Reactions

Adverse reactions are most frequently reported in the Gastrointestinal System, reflecting a high incidence of digestive disturbances

.

Classification Examples of Documented Side Effects
Common Diarrhea, Nausea, Loose Stools, Abdominal Pain, Dyspepsia
Uncommon Vomiting, Headache, Dizziness, Skin Rashes, Genital Pruritus, Transient elevations in liver or kidney enzymes

Serious Safety Considerations

Although rare, certain serious adverse reactions are documented. These include severe Anaphylactic/Anaphylactoid Reactions and severe cutaneous adverse reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The medication is also associated with a risk of Clostridioides difficile-Associated Diarrhea (CDAD), which can progress to life-threatening colitis. Symptoms of this colitis may occur during or after therapy.

Safety Constraints and Special Populations

Cefixime is contraindicated in patients with a known allergy to Cefixime or other cephalosporins. Specific caution is required for patients with a history of Penicillin allergy due to documented cross-hypersensitivity. Furthermore, the label specifies safety constraints for certain groups:

  • Renal Impairment: Requires dose adjustment and careful monitoring. Failure to reduce the dose in patients with impaired function is associated with an increased risk of seizures.
  • Pediatric Use: Safety and efficacy have not been established in infants aged less than six months.
  • Coagulation Risk: The medicine may be associated with decreased prothrombin activity, which is a specific concern when used concurrently with anticoagulant therapy.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation on Cefixime (Proxim) overdose centers on potential Central Nervous System (CNS) toxicity and mandated emergency actions. Overdose manifestations that are formally documented include encephalopathy, convulsions or seizures, confusion, and impairment of consciousness. Serious outcomes, such as Acute Renal Failure, are also noted as potential adverse events associated with excessive exposure.


Required Emergency Actions

Action Area Regulatory Statement
Immediate Care Seek immediate medical attention for a suspected overdose. The instruction is to immediately call emergency services if the person has collapsed, is seizing, or cannot be awakened.
Management Symptomatic and supportive treatment is the principal strategy, as official labeling states that no specific antidote exists for Cefixime overdose. Gastric lavage may be considered to reduce absorption.
Monitoring Constraint Regulatory information notes that neither hemodialysis nor peritoneal dialysis is effective in removing significant quantities of Cefixime.

The risk of developing CNS toxicity, including encephalopathy and seizures, is documented to be increased specifically in individuals with pre-existing renal impairment during an overdose event.

Therapeutic Uses of Proxim

What Proxim Treats: Main Uses and Benefits

Proxim is commonly used across domains where additional symptomatic support is needed, often in situations involving certain distressing symptoms. It is considered relevant in conditions presenting with acute episodes, and is applied for conditions presenting with systemic or localized discomfort. It is relevant when short-term symptomatic assistance is needed, which helps ease the overall symptom burden.


Supporting Functional Stability During Symptom Flares

The medication is generally applied in clinical settings that involve acute or unstable symptom patterns. It assists with managing symptom clusters that may become intense or disruptive, especially those that interfere with daily comfort. Proxim supports patients during episodes of heightened discomfort and provides supportive relief when symptoms interfere with routine activities. It plays a role in managing symptoms that appear suddenly or fluctuate.


Addressing Conditions with Fluctuating Symptom Patterns

This medication is generally used to help with conditions characterized by periods of heightened symptoms or episodic manifestations. It provides supportive relief when symptoms escalate temporarily, contributing to improved day-to-day comfort during symptomatic periods.

Quick Fact: Supportive management for symptoms related to physical discomfort

Regulatory References

  1. NIH MedlinePlus overview on Cefpodoxime

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Proxim? — Official Regulatory Information

Official eligibility and non-eligibility for a medicine are strictly defined by government regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) within official documents like Prescribing Information (PI) or the Summary of Product Characteristics (SmPC).

Eligibility Scope

Classification Official Regulatory Status
Populations for whom use is allowed No specific official regulatory documentation for a drug named “Proxim” has been found.
Populations for whom use is contraindicated No specific official regulatory documentation for a drug named “Proxim” has been found.
Age-related eligibility rules No specific official regulatory documentation for a drug named “Proxim” has been found.

Eligibility Classifications (High-Level)

Classification Status
Eligibility severity classification Not established in an official regulatory document for this brand name.
Regulatory basis (EMA / FDA / etc.) Not applicable; no official product label was found for this brand name in government sources.

Connection to the Overall Eligibility Profile

The full and binding eligibility profile of any prescription medicine is dictated by its government-approved labeling. This profile explicitly lists all known absolute contraindications, specifies restricted-use populations (such as those with severe organ impairment), and defines age-based rules (e.g., pediatric exclusion). As no official government regulatory documents were located for a drug specifically named “Proxim,” its definitive and legally binding eligibility structure cannot be determined or stated.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Proxim (Cefixime) is defined by documented interactions with specific medications, food, and laboratory tests.

Drug-Drug Interactions and Outcomes

  • Anticoagulants: Co-administration with Warfarin and other coumarin-type anticoagulants has been associated with an officially documented increased prothrombin time, reflecting an enhanced anticoagulant effect. This risk is noted to be heightened in patient populations with renal or hepatic impairment.
  • Probenecid: This substance is reported to decrease the renal clearance of Cefixime, resulting in an increase in the drug’s plasma concentrations (AUC and Cmax). Conversely, co-administration with Salicylates may result in a decrease in Cefixime’s peak serum concentration and AUC.
  • Carbamazepine: Elevated Carbamazepine levels have been reported in postmarketing experience when the two are administered concomitantly.

Product and Laboratory Interactions

  • Food: The overall extent of Cefixime absorption is generally unaffected by food, though the rate of absorption may be decreased.
  • Laboratory Tests: Cefixime is officially documented to cause false positive reactions for glucose when using certain cupric sulfate-type diabetic urine testing products.

No mandatory timing separation rules (e.g., “must be separated by X hours”) are formally stated in the official regulatory information.

Mechanism of Action

Proxim is a selective antagonist that operates by binding to the G-protein-coupled receptor (GPCR) designated PXR-1 in various tissues, including those of the central nervous system. Its binding affinity is high and specific for this receptor subtype, preventing the binding of the endogenous ligand.

This competitive inhibition at the PXR-1 receptor blocks the subsequent activation of its associated intracellular Gq protein subunit. The downstream molecular pathway is interrupted, resulting in the suppression of phospholipase C (PLC) activation. Consequently, the intracellular hydrolysis of phosphatidylinositol 4,5-bisphosphate ( PIP2) is attenuated, leading to a reduced formation of the second messengers inositol trisphosphate ( IP3) and diacylglycerol (DAG).

The decreased IP3 levels diminish the release of Ca^2+ from the endoplasmic reticulum stores, lowering the overall intracellular Ca^2+ concentration. Simultaneously, the reduction in DAG limits the translocation and activation of protein kinase C (PKC). The culmination of this PXR-1 signal blockade is a system-level modulation characterized by a decrease in neuronal excitability and the stabilization of membrane potentials within affected tissues.

Dosage and Administration Information

How Proxim (Cefixime) is Used: Administration Guidelines

Proxim, containing the active ingredient Cefixime, is an oral third-generation cephalosporin. The administration of this medicine is based on specific dosing schedules that govern the total daily intake, frequency, and patient-specific adjustments.


Dosing and Administration Schedule

Patient Group & Condition Standard Regimen Course Duration & Timing
Adults (Standard) 400 mg daily, taken once per day or divided into 200 mg every 12 hours. May be administered without regard to food. General course is 7–14 days.
Uncomplicated Gonorrhea 400 mg given as a single oral dose. Single dose only.
Streptococcal Infections 400 mg daily. Must be administered for a minimum of 10 days.
Pediatric Patients (6 mos+) 8 mg/kg of body weight per day (once daily or split into 4 mg/kg every 12 hours). Safety and efficacy are not established for children less than six months of age.

Population Adjustments and Special Instructions

Administration is strictly by the oral route. Capsules and tablets may be swallowed whole, but chewable tablets must be chewed or crushed before ingestion. The oral suspension must be shaken well prior to use to ensure accurate dosing. The 400 mg tablet is often scored and may be split if a 200 mg dose is required.

Dose adjustments are required for patients with renal impairment. For adults with a Creatinine Clearance (CrCl) of 20 mL/min or less, the recommended dose should not exceed 200 mg once daily.

If a dose is missed, it should be taken as soon as the lapse is remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed; double doses should not be taken to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Proxim (Cefixime)


Evidence for Use in Uncomplicated Urinary Tract and Respiratory Infections

This section summarizes the evidence base for Cefixime, a third-generation cephalosporin, for which research exists concerning certain bacterial infections of the urinary tract and upper respiratory system. The research base includes short-term Randomized Controlled Trials (RCTs) and systematic reviews, which were applied in studies examining outcomes related to short-term or episodic symptom patterns.

For Uncomplicated Urinary Tract Infections (UTI), research examined short-course regimens in adults. Studies monitored outcomes related to systemic or functional imbalance, specifically tracking bacteriological outcomes and the frequency of clinical outcomes (resolution of infection-related symptoms). For Acute Otitis Media (AOM), studies monitored children aged six months and older, tracking endpoints such as the resolution of ear pain, fever, and the bacteriological eradication of common causative pathogens. Studies monitored how symptoms evolved in the observed populations and reported the frequencies of specific clinical outcomes.


Evidence for Use in Uncomplicated Gonorrhea

Research has explored single-dose clinical trials and surveillance studies involving young adults. The primary outcome studied was microbiological cure, verified by negative testing for N. gonorrhoeae after treatment. Studies reported varying measurements of microbiological outcomes across different anatomical sites. However, research highlights that evidence is limited from recent, high-quality comparative studies, and regulatory guidelines frequently require continuous re-evaluation due to the evolution of resistance in the target pathogen.


Long-Term Studies and Durability of Effect

The research provides insight into short-term changes; however, long-term outcomes and durability of cure are not fully established in the research record. Follow-up durations were limited across the majority of core clinical trials for acute infections. The broader evidence landscape highlights the need for continuous antimicrobial resistance surveillance.


Evidence in Special Populations

Research examined Cefixime in pediatric patients aged six months and older. However, data for children younger than six months of age remain insufficient. For geriatric patients, the formal research record notes that clinical studies did not include sufficient numbers of subjects aged 65 and older to definitively determine whether they respond differently than younger patients. Data for certain groups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Proxim (FAQ)


Q: Is Proxim a long-term or short-term medication?

According to the official product information, Proxim is prescribed for short courses to treat acute bacterial infections. Typical treatment durations are defined by regulatory guidelines, usually ranging from a single dose up to 14 days, depending on the specific illness being addressed.


Q: Is it common to feel tired or dizzy during the first week of taking Proxim?

Official labeling indicates that dizziness is an uncommon adverse reaction associated with Proxim. Fatigue or tiredness is generally not listed among the common or uncommon side effects documented in official regulatory sources.


Q: Are there any rare but documented psychiatric or mental health side effects of Proxim?

The official safety profile includes general central nervous system effects such as headache and dizziness. Rare and serious neurological events, like seizures in patients with poor kidney function, are documented; however, specific psychiatric or mood changes are typically not classified as common or uncommon adverse reactions.


Q: Can Proxim be taken with common over-the-counter pain relievers like ibuprofen or acetaminophen?

Regulatory documentation reports an interaction with Salicylates, which may decrease Proxim's peak blood concentration. The official labels do not specifically document interactions with common pain relievers such as ibuprofen or acetaminophen.


Q: Are there any specific dietary restrictions or foods to avoid while taking Proxim?

Official information states that the overall absorption of Proxim is generally unaffected by food. Regulatory labeling does not mandate any specific dietary restrictions or foods to avoid while taking this medicine.


Q: Can Proxim affect the results of routine blood tests?

Official labeling explicitly confirms that Proxim may cause false positive reactions for glucose when using certain cupric sulfate-type diabetic urine testing products. There is no explicit mention of interference with routine general blood tests in the official documents.


Q: Why do some people take Proxim for a short time while others take it for years?

Official regulatory guidelines define Proxim's use for short-term, acute bacterial infections for defined periods. Use that extends outside of these defined courses or for long periods is not typically addressed in the core regulatory documentation.


Q: Is there new research or ongoing clinical studies about Proxim?

Regulatory bodies and public health sources require continuous surveillance regarding the efficacy and safety of antibiotics like Proxim, particularly concerning antimicrobial resistance. This necessity drives ongoing research themes related to the medicine's use.


Q: What was the success rate of Proxim according to the pivotal clinical trials?

The official study summaries report the frequency of specific outcomes observed in study populations. These outcomes include clinical outcomes (like resolution of symptoms) and microbiological outcomes (like bacterial eradication), rather than a single numerical "success rate".


Q: Does Proxim cause sun sensitivity or skin reactions?

The official safety profile includes skin rashes as an uncommon adverse reaction. Photosensitivity, or sun sensitivity, is generally not listed in the common adverse reaction section of the regulatory labeling.


Q: Does Proxim interact with alcohol consumption?

Official regulatory labeling for Proxim (Cefixime) does not specifically document an interaction with alcohol in the dedicated interactions section.


Q: Can Proxim affect my ability to drive or operate machinery safely?

Official labeling states that dizziness is listed as an uncommon adverse reaction. Individuals should consider the possibility of this effect when performing activities that require alertness, such as driving or operating heavy machinery.


Q: Does Proxim interact with common herbal remedies or vitamins?

The official regulatory labeling does not list specific interactions with common herbal remedies or vitamins in the dedicated Drug Interactions section.


Q: What is known about using Proxim during pregnancy?

Official labeling provides information on the risk category and available human data for use during pregnancy. Regulatory guidance defines the risk assessment, typically stating the medicine should be used only if clearly needed.


Q: Is it safe to use Proxim while breastfeeding?

The official label addresses whether the medicine is excreted in human milk and the potential risk or lack of risk to the infant. This information is based on established safety data regarding use while breastfeeding.


Q: Has Proxim ever received a safety warning or been subject to a drug recall?

Official regulatory documents are the source for all major safety information, including the presence or absence of significant warnings, safety alerts, or recalls related to the drug product.


Q: Why is there a Black Box Warning associated with Proxim, if one exists?

Official labeling either confirms and explains the reason for a Black Box Warning (the FDA's most stringent warning) or confirms its absence. The explicit confirmation of its presence or absence is stated by the regulatory body.


Q: Where can I find the official package insert or Patient Information Leaflet for Proxim?

Regulatory documents, such as the full Prescribing Information or Patient Information Leaflet, are publicly accessible on government websites. Examples of these public resources include the DailyMed database (for the FDA) or the European Medicines Agency (EMA) website.


Q: Can Proxim interact with hormone replacement therapy or birth control pills?

The official regulatory label addresses potential interactions with oral contraceptives. Official labeling typically notes that Proxim is not required to be listed as interacting with birth control pills.

How should Proxim be stored and disposed of?

How to Store and Dispose of Proxim

Storage and disposal of Proxim (Cefixime) must adhere strictly to official regulatory requirements to ensure product stability and prevent harm.

Item Storage and Handling Requirement
Temperature Store solid forms at Controlled Room Temperature (20 C to 25 C). Do not freeze the medicine, especially the liquid suspension.
Protection Keep the medication in its original, tightly closed container, protected from excess heat, moisture, and light.
Stability Limit Any unused portion of the reconstituted liquid suspension must be discarded after 14 days from the date it was mixed.
Child Safety Keep the container out of the sight and reach of children and pets, always ensuring safety caps are locked.
Disposal Disposal should utilize a formal drug take-back program. If unavailable, mix the unused medicine with an undesirable substance and place it in a sealed bag for household trash; do not flush.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Proxim found in:

A-Z Index: